Comprehensive Stock Comparison
Compare argenx SE (ARGX) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ARGX | 78.6% revenue growth vs CANF's -9.3% |
| Quality / Margins | ARGX | 23.3% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs ARGX's 0.44 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs ARGX's +22.8% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs CANF's -114.0%, ROIC -0.5% vs -448.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ARGX leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). CANF leads in 2 (Valuation Metrics, Risk & Volatility).
Financial Metrics (TTM)
ARGX is the larger business by revenue, generating $4.0B annually — 7060.4x CANF's $560,000. ARGX is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to CANF's -15.7%. On growth, ARGX holds the edge at +5.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $4.0B | $560,000 |
| EBITDAEarnings before interest/tax | $95M | -$9M |
| Net IncomeAfter-tax profit | $923M | -$9M |
| Free Cash FlowCash after capex | $213M | -$8M |
| Gross MarginGross profit ÷ Revenue | +75.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -1.0% | -16.0% |
| Net MarginNet income ÷ Revenue | +23.3% | -15.7% |
| FCF MarginFCF ÷ Revenue | +5.4% | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.1% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.6% | +36.4% |
Valuation Metrics
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $47.5B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $46.0B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | 60.01x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.57x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 21.67x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 9.09x | 6.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-2 for CANF. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CANF's 0.02x. On the Piotroski fundamental quality scale (0–9), ARGX scores 3/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | +15.1% | -2.1% |
| ROA (TTM)Return on assets | +12.9% | -114.0% |
| ROICReturn on invested capital | -0.5% | -4.5% |
| ROCEReturn on capital employed | -0.4% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | 0.01x | 0.02x |
| Net DebtTotal debt minus cash | -$1.5B | -$5M |
| Cash & Equiv.Liquid assets | $1.5B | $5M |
| Total DebtShort + long-term debt | $39M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | 166.64x | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in ARGX five years ago would be worth $22,521 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs ARGX's +22.8%. The 3-year compound annual growth rate (CAGR) favors ARGX at 28.0% vs CANF's 20.6% — a key indicator of consistent wealth creation.
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | -8.7% | +2059.1% |
| 1-Year ReturnPast 12 months | +22.8% | +169.9% |
| 3-Year ReturnCumulative with dividends | +109.5% | +75.3% |
| 5-Year ReturnCumulative with dividends | +125.2% | -76.5% |
| 10-Year ReturnCumulative with dividends | +3234.4% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +28.0% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than ARGX's 0.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs ARGX's 82.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.44x | 0.36x |
| 52-Week HighHighest price in past year | $934.62 | $4.93 |
| 52-Week LowLowest price in past year | $510.06 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +82.1% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 33.9 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 301K | 4.3M |
Analyst Outlook
Wall Street rates ARGX as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 33.9% for ARGX (target: $1027).
| Metric | ARGXargenx SE | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1026.71 | $7.25 |
| # AnalystsCovering analysts | 35 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| argenx SE (ARGX) | 100 | 564.69 | +464.7% |
| Can-Fite BioPharma … (CANF) | 100 | 32.52 | -67.5% |
argenx SE (ARGX) returned +125% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%. A $10,000 investment in ARGX 5 years ago would be worth $22,521 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| argenx SE (ARGX) | $7M | $2.2B | +29130.4% |
| Can-Fite BioPharma … (CANF) | $164717.00 | $674000.00 | +309.2% |
argenx SE's revenue grew from $7M (2015) to $2.2B (2024) — a 87.9% CAGR. Can-Fite BioPharma Ltd.'s revenue grew from $0M (2015) to $1M (2024) — a 16.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| argenx SE (ARGX) | -2.2% | 38.0% | +1802.4% |
| Can-Fite BioPharma … (CANF) | -29.1% | -11.7% | +59.9% |
argenx SE's net margin went from -2% (2015) to 38% (2024). Can-Fite BioPharma Ltd.'s net margin went from -29% (2015) to -12% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| argenx SE (ARGX) | -1.06 | 12.78 | +1305.7% |
| Can-Fite BioPharma … (CANF) | -81 | -1.08 | +98.7% |
argenx SE's EPS grew from $-1.06 (2015) to $12.78 (2024). Can-Fite BioPharma Ltd.'s EPS grew from $-81.00 (2015) to $-1.08 (2024).
Chart 5Free Cash Flow — 5 Years
argenx SE generated $-151M FCF in 2024 (+79% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
ARGX vs CANF: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARGX or CANF a better buy right now?
argenx SE (ARGX) offers the better valuation at 60.0x trailing P/E (25.6x forward), making it the more compelling value choice. Analysts rate argenx SE (ARGX) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARGX or CANF?
Over the past 5 years, argenx SE (ARGX) delivered a total return of +125.2%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in ARGX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARGX or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus argenx SE's 0.44β — meaning ARGX is approximately 22% more volatile than CANF relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 2% for Can-Fite BioPharma Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ARGX or CANF?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARGX leads at -1.0% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ARGX or CANF more undervalued right now?
Analyst consensus price targets imply the most upside for CANF: 52.6% to $7.25.
06Which pays a better dividend — ARGX or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ARGX or CANF better for a retirement portfolio?
For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44)). Both have compounded well over 10 years (ARGX: +32.3%, CANF: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARGX and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.